HHS sends peptide 'interim access policy' to White House review, a step toward letting pharmacies compound BPC-157

The Department of Health and Human Services submitted an interim access policy on peptides to the White House Office of Management and Budget for review, according to a government posting on Thursday. People familiar with the plan said it would let compounding pharmacies temporarily make some popular peptides, including BPC-157, without FDA enforcement, while permanent changes would still need rulemaking. Major telehealth providers have said they plan to offer peptides if access is eased; analysts put the market at $2 billion to $3 billion.

• Policy sent to OMB for review; text not yet public
• Would use FDA enforcement discretion for some peptides, including BPC-157
• Analysts estimate the peptide market at $2B-$3B